> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Generic User Fee Negotiations Offer Proposals
- URL: https://www.fdaweb.com/fda-generic-user-fee-negotiations-offer-proposals/
- Published: 2025-11-17T12:00:00.000Z
- Updated: 2026-09-14T15:26:51.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5160225

FDA and generic drug manufacturers kicked off formal negotiations on the next cycle of the Generic Drug User Fee Amendments (GDUFA IV) during a recent meeting at the agency’s White Oak campus, which saw both parties offer several operating proposals. Negotiations began by establishing ground rules intended to keep the months-long process on track, including expectations for proposal submission, confirming agreements, and limiting external communications while talks are underway, according to [meeting minutes ](https://www.fda.gov/media/189620/download?attachment&ref=fdaweb.com)posted online.

FDA and industry offered opening statements assessing achievements and ongoing friction points under GDUFA III. Industry raised concerns about FDA resource constraints and recent budget pressures, warning that these could affect the agency’s ability to meet review commitments.

FDA and industry next exchanged initial high-level proposals across several categories:

- **Revenue and Fee Structure:** Both sides proposed changes to the user fee framework aimed at ensuring long-term financial stability of the generic drug program.
- **Standardization Across User Fee Programs:** FDA proposed harmonizing certain statutory fee and financial management provisions with other user fee programs; industry did not offer counterproposals.
- **Reducing ANDA Review Cycles:** Both sides floated ideas to improve applicant support and streamline processes to cut the number of review cycles for abbreviated new drug applications.
- **Program Efficiency:** Proposals focused on enhanced communications, greater transparency, and standardized submission formats, including for complex generics.
- **Data Fidelity:** FDA outlined a plan to address data integrity problems at manufacturing sites and contract research organizations; industry offered no proposals in this category.
- **Onshoring Incentives:** FDA proposed exploring incentives for companies that manufacture or conduct studies in the U.S. Industry said it needs more detail to determine whether such incentives fall within GDUFA’s negotiating scope.

The meeting concluded with agreement to cluster proposals into thematic groups and to develop a schedule for deeper dives at upcoming sessions, according to the minutes. FDA and industry plan to hold a planning meeting to coordinate timelines and determine which proposals fall within the formal negotiating scope.